keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous immunotherapy

keyword
https://www.readbyqxmd.com/read/28526774/preliminary-evaluation-of-cytosine-phosphate-guanine-oligodeoxynucleotides-bound-to-gelatine-nanoparticles-as-immunotherapy-for-canine-atopic-dermatitis
#1
I Wagner, K J Geh, M Hubert, G Winter, K Weber, J Classen, C Klinger, R S Mueller
Cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) are a promising new immunotherapeutic treatment option for canine atopic dermatitis (AD). The aim of this uncontrolled pilot study was to evaluate clinical and immunological effects of gelatine nanoparticle (GNP)-bound CpG ODN (CpG GNP) on atopic dogs. Eighteen dogs with AD were treated for 8 weeks (group 1, n=8) or 18 weeks (group 2, n=10). Before inclusion and after 2 weeks, 4 weeks, 6 weeks (group 1+2), 8 weeks, 12 weeks and 16 weeks (group 2) 75 µg CpG ODN/dog (bound to 1...
May 19, 2017: Veterinary Record
https://www.readbyqxmd.com/read/28525399/allergen-immunotherapy-for-the-treatment-of-respiratory-allergies-in-the-elderly
#2
Gyu-Young Hur, Ji-Ho Lee, Hae-Sim Park
PURPOSE OF REVIEW: Respiratory allergies, including asthma and allergic rhinitis can also occur in the elderly. Allergen immunotherapy for allergic diseases is the only disease-modifying treatment for patients with allergies available thus far. Here, we review current evidence supporting the use of allergen immunotherapy in the elderly and discuss its efficacy and utility for the treatment of respiratory allergic diseases in this setting. RECENT FINDINGS: Subcutaneous and/or sublingual immunotherapy are effective therapeutic options in not only young but also older patients...
May 17, 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28515940/nivolumab-induced-autoimmune-diabetes-mellitus-presenting-as-diabetic-ketoacidosis-in-a-patient-with-metastatic-lung-cancer
#3
James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D Rao, Ranee Mehra, Colleen Veloski
BACKGROUND: Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence of autoimmune side effects associated with these agents, termed immune related adverse events (irAE), is expected to increase. The frequency of significant irAE in ICI treated patients is about 10-20% and early recognition is critical to prevent serious morbidity and even mortality...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28506308/attenuating-immune-pathology-using-a-microbial-based-intervention-in-a-mouse-model-of-cigarette-smoke-induced-lung-inflammation
#4
Mark Bazett, Agnieszka Biala, Ryan D Huff, Matthew R Zeglinksi, Philip M Hansbro, Momir Bosiljcic, Hal Gunn, Shirin Kalyan, Jeremy A Hirota
BACKGROUND: Cigarette smoke exposure is the major risk factor for developing COPD. Presently, available COPD treatments focus on suppressing inflammation and providing bronchodilation. However, these options have varying efficacy in controlling symptoms and do not reverse or limit the progression of COPD. Treatments strategies using bacterial-derived products have shown promise in diseases characterized by inflammation and immune dysfunction. This study investigated for the first time whether a novel immunotherapy produced from inactivated Klebsiella (hereafter referred to as KB) containing all the major Klebsiella macromolecules, could attenuate cigarette smoke exposure-induced immune responses...
May 15, 2017: Respiratory Research
https://www.readbyqxmd.com/read/28502133/t-regulatory-cells-response-to-allergen-specific-immunotherapy-in-patients-with-allergic-airway-diseases-a-prospective-study
#5
Raghdaa A Ramadan, Emad A Morad, Mohamed El-Shabrawy
Forkhead box P3 (FoxP3) T regulatory (Treg) cells modulate the immune system by blocking other types of T-cells. They maintain tolerance to self-antigens and help in inducing tolerance to foreign antigens. A deregulation of FoxP3 Tregs seems to play an important role in allergic disorders. The aim of this work was to study the response of FoxP3 Treg cells and their FoxP3 expression in patients, attending the Allergy Unit and the Chest Outpatient Clinic, Faculty of Medicine, Zagazig University, with allergic airway diseases, before and 1 year after receiving subcutaneous allergen specific immunotherapy (SIT)...
June 2016: Egyptian Journal of Immunology
https://www.readbyqxmd.com/read/28497677/successful-of-subcutaneous-and-oral-hyposensitizing-therapy-in-30-patients
#6
A Tammaro, I Romano, F R Parisella, G De Marco, F Persechino, I Trimarchi, S Persechino
Background. Pharmacotherapy and immunotherapy are the main treatment modalities for respiratory allergy. The aim of this paper has been to evaluate the efficacy and tolerability of subcutaneous and sublingual immunotherapy in association in allergic patients, and to demonstrate that the patients who have performed a second oral vaccination cycle after 4-5 years from the first subcutaneous treatment, derive benefits that may last for years. This is due to immune system's plasticity. Methods. The study was conducted in 30 allergic patients which had previously executed a full cycle of classical subcutaneous immunotherapy, with a partial remission of symptoms...
May 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28497671/perceived-efficacy-and-satisfaction-of-patients-with-subcutaneous-hypoallergenic-high-dose-house-dust-mite-extract
#7
A Roger Reig, M Ibero Iborra, T Carrillo Díaz, R López Abad, V Sánchez Moreno, J Álvarez Nieto, N Cancelliere
The efficacy and safety of subcutaneous immunotherapy with modified, high-dose, major allergen house dust mite extract is widely supported by double-blind, placebo-controlled studies. However, little is known regarding patient-perceived efficacy and satisfaction. An observational, retrospective, multicentre study in patients treated with Acaroid(®) was conducted to assess the efficacy and degree of satisfaction of the patients after the first six months of treatment with it. All the clinical study procedures were performed according to the routine clinical practice...
May 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28495938/allergen-immunotherapy-for-the-treatment-of-allergic-rhinitis-and-or-asthma-an-umbrella-review
#8
Jesse Elliott, Shannon E Kelly, Amy Johnston, Becky Skidmore, Tara Gomes, George A Wells
BACKGROUND: Allergic rhinitis and asthma are important public health concerns, yet there is no consensus about the benefits and harms of allergen-specific immunotherapy to treat these conditions. We performed an umbrella review of systematic reviews summarizing the current evidence for the benefits and harms of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). METHODS: We searched MEDLINE, Embase, the Cochrane Library and the grey literature from Jan...
May 10, 2017: CMAJ Open
https://www.readbyqxmd.com/read/28487839/changes-in-skin-reactivity-and-associated-factors-in-patients-sensitized-to-house-dust-mites-after-1-year-of-allergen-specific-immunotherapy
#9
Jeong-Yeop Son, Mann-Hong Jung, Kwang-Wook Koh, Eun-Kee Park, Jeong-Hoon Heo, Gil-Soon Choi, Hee-Kyoo Kim
BACKGROUND: Allergen-specific immunotherapy (SIT) can significantly improve symptoms and reduce the need for symptomatic medication. OBJECTIVE: The aim of this study was to investigate changes in skin reactivity to house dust mites (HDMs) as an immunologic response and associated factors after 1 year of immunotherapy. METHODS: A total of 80 patients with allergic airway diseases who received subcutaneous SIT with HDMs from 2009 to 2014 were evaluated...
April 2017: Asia Pacific Allergy
https://www.readbyqxmd.com/read/28484690/subcutaneous-and-sublingual-immunotherapy-in-allergic-asthma-in-children
#10
REVIEW
Sophia Tsabouri, Antigoni Mavroudi, Gavriela Feketea, George V Guibas
This review presents up-to-date understanding of immunotherapy in the treatment of children with allergic asthma. The principal types of allergen immunotherapy (AIT) are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Both of them are indicated for patients with allergic rhinitis and/or asthma, who have evidence of clinically relevant allergen-specific IgE, and significant symptoms despite reasonable avoidance measures and/or maximal medical therapy. Studies have shown a significant decrease in asthma symptom scores and in the use of rescue medication, and a preventive effect on asthma onset...
2017: Frontiers in Pediatrics
https://www.readbyqxmd.com/read/28474505/house-dust-mite-specific-immunotherapy-with-two-licensed-vaccines-outcome-under-clinical-routine-conditions
#11
Vera Mahler, Christian Klein, Angelika Sager, Jürgen Zimmermann
INTRODUCTION: House dust mite (HDM) allergens are major causes for the development of allergic diseases. A disease modifying effect and clinical benefit of allergen immunotherapy (AIT) has been demonstrated in a number of clinical trials. Clinical trials, however, are carried out in selected populations under specific conditions based on inclusion and exclusion criteria and may not represent the entire patient population from medical practice. Objective of this study conducted in patients with HDM allergy was to systematically collect information about the benefit of AIT under clinical routine conditions...
June 2017: Immunity, Inflammation and Disease
https://www.readbyqxmd.com/read/28468884/antibody-preparations-from-human-transchromosomic-cows-exhibit-prophylactic-and-therapeutic-efficacy-versus-venezuelan-equine-encephalitis-virus
#12
Christina L Gardner, Chengqun Sun, Thomas Luke, Kanakatte Raviprakash, Hua Wu, Jin-An Jiao, Eddie Sullivan, Douglas S Reed, Kate D Ryman, William B Klimstra
Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne RNA virus that causes low mortality but high morbidity in humans. In addition to natural outbreaks, there is potential for exposure to VEEV via aerosolized virus particles. There are currently no FDA-licensed vaccines or antiviral therapies for VEEV. Passive immunotherapy is an approved method used to treat individuals against several pathogens and toxins. Human polyclonal antibodies (pAbs) are ideal, but this is dependent upon serum from convalescent human donors, which is in limited supply...
May 3, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28451054/molecular-fingerprinting-of-complex-grass-allergoids-size-assessments-reveal-new-insights-in-epitope-repertoires-and-functional-capacities
#13
S Starchenka, A J Bell, J Mwange, M A Skinner, M D Heath
BACKGROUND: Subcutaneous allergen immunotherapy (SCIT) is a well-documented treatment for allergic disease which involves injections of native allergen or modified (allergoid) extracts. The use of allergoid vaccines is a growing sector of the allergy immunotherapy market, associated with shorter-course therapy. The aim of this study was the structural and immunological characterisation of group 1 (Lol p 1) IgG-binding epitopes within a complex mix grass allergoid formulation containing rye grass...
2017: World Allergy Organization Journal
https://www.readbyqxmd.com/read/28439064/immunotherapy-of-dual-function-vector-with-both-immunostimulatory-and-b-cell-lymphoma-2-bcl-2-silencing-effects-on-gastric-carcinoma
#14
Lanying Ma, Mei Han, Zumureti Keyoumu, Hua Wang, Saifuding Keyoumu
BACKGROUND Tumorigenesis is a kind of pathology marked by infinite proliferation and restrained apoptosis compared with normal cells. The abnormal expression of some proto-oncogenes and apoptosis inhibition are essential for tumor growth, which has been confirmed by molecular biologic and immunologic studies. The hypofunction of the host immune system also drives the development and metastasis of malignant tumors. Bcl-2, which has a critical role in regulating apoptosis, is overexpressed in several cancers...
April 25, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28432037/investigating-in-vitro-and-in-vivo-%C3%AE-v%C3%AE-6-integrin-receptor-targeting-liposomal-alendronate-for-combinatory-%C3%AE-%C3%AE-t-cell-immunotherapy
#15
Naomi O Hodgins, Wafa' T Al-Jamal, Julie T-W Wang, Rebecca Klippstein, Pedro M Costa, Jane K Sosabowski, John F Marshall, John Maher, Khuloud T Al-Jamal
The αvβ6 integrin receptor has been shown to be overexpressed on many types of cancer cells, resulting in a more pro-invasive and aggressive phenotype, this makes it an attractive target for selective drug delivery. In tumours that over-express the αvβ6 receptor, cellular uptake of liposomes can be enhanced using ligand-targeted liposomes. It has previously been shown in both in vitro and in vivo studies that liposomal alendronate (L-ALD) can sensitise cancer cells to destruction by Vγ9Vδ2 T cells. It is hypothesised that by using the αvβ6-specific peptide A20FMDV2 as a targeting moiety for L-ALD, the therapeutic efficacy of this therapy can be increased in αvβ6 positive tumours...
April 18, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28430664/identification-of-a-novel-pd-l1-positive-solid-tumor-transplantable-in-hla-a-0201-drb1-0101-transgenic-mice
#16
Laurie Rangan, Jeanne Galaine, Romain Boidot, Mohamad Hamieh, Magalie Dosset, Julie Francoual, Laurent Beziaud, Jean-René Pallandre, Elodie Lauret Marie Joseph, Afag Asgarova, Christophe Borg, Talal Al Saati, Yann Godet, Jean Baptiste Latouche, Séverine Valmary-Degano, Olivier Adotévi
HLA-A*0201/DRB1*0101 transgenic mice (A2/DR1 mice) have been developed to study the immunogenicity of tumor antigen-derived T cell epitopes. To extend the use and application of this mouse model in the field of antitumor immunotherapy, we described a tumor cell line generated from a naturally occurring tumor in A2/DR1 mouse named SARC-L1. Histological and genes signature analysis supported the sarcoma origin of this cell line. While SARC-L1 tumor cells lack HLA-DRB1*0101 expression, a very low expression of HLA-A*0201 molecules was found on these cells...
April 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28428054/modified-nanoparticle-mediated-il-12-immunogene-therapy-for-colon-cancer
#17
Xiaoxiao Liu, Xiang Gao, Songping Zheng, Bilan Wang, Yanyan Li, Chanjuan Zhao, Yagmur Muftuoglu, Song Chen, Ying Li, Haiyan Yao, Hui Sun, Qing Mao, Chao You, Gang Guo, Yuquan Wei
For the past few years, immunotherapy has recently shown considerable clinical benefit in CRC therapy, and the application of immunologic therapies in cancer treatments continues to increase perennially. Interleukin-12, an ideal candidate for tumor immunotherapy, could activate both innate and adaptive immunities. In this study, we developed a novel gene delivery system with a self-assembly method by MPEG-PLA and DOTAP(DMP) with zeta-potential value of 38.5mV and size of 37.5nm. The supernatant of lymphocytes treated with supernatant from Ct26 transfected pIL12 with DMP could inhibit Ct26 cells growth ex vivo...
April 17, 2017: Nanomedicine: Nanotechnology, Biology, and Medicine
https://www.readbyqxmd.com/read/28417212/lalf32-51-e7-therapeutic-vaccine-induces-antitumor-immunity-against-human-papillomavirus-type-16-e7-expressing-murine-tumor-metastases-in-the-lungs
#18
Milaid Granadillo, Aileen Batte, Aracelys Blanco, Alain B Alfonso, José Suárez, Nelson Merino, Rosalina Carballo, Bárbara O González, Yayrí C Prieto, Laura Varas, Dayana Soler, Miladys Limonta, Maelys Miyares, Lizet Aldana, Isis Torrens
One important goal of cancer immunotherapy is to prevent and treat tumor metastasis. We have previously reported the significant antitumor effect induced by the immunization with our human papillomavirus therapeutic protein-based vaccine (LALF32-51-E7) without adjuvant and admixed with clinically relevant adjuvants in the subcutaneous TC-1 tumor challenge model. In the present study, we evaluated the efficacy of the above mentioned vaccine formulations in controlling the hematogenous spread of TC-1 tumor cells using a more tumourigenic clone named TC-1* and other intravenous injection site less stressful than the tail vein...
April 17, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28416261/feasibility-study-of-personalized-peptide-vaccination-for-advanced-small-cell-lung-cancer
#19
Shinjiro Sakamoto, Teppei Yamada, Yasuhiro Terazaki, Koichi Yoshiyama, Shunichi Sugawara, Shinzo Takamori, Satoko Matsueda, Shigeki Shichijo, Akira Yamada, Masanori Noguchi, Kyogo Itoh, Noboru Hattori, Nobuoki Kohno, Tetsuro Sasada
INTRODUCTION: The prognosis of patients with small cell lung cancer (SCLC) remains very poor. Therefore, the development of new therapeutic approaches, including immunotherapies, is desirable. PATIENTS AND METHODS: We conducted a phase II study of personalized peptide vaccination (PPV), in which a maximum of 4 human leukocyte antigen-matched peptides were selected from 31 pooled peptides according to the pre-existing peptide-specific IgG responses before vaccination...
March 24, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28414151/targeted-antigen-delivery-to-dendritic-cell-via-functionalized-alginate-nanoparticles-for-cancer-immunotherapy
#20
Chuangnian Zhang, Gaona Shi, Ju Zhang, Huijuan Song, Jinfeng Niu, Shengbin Shi, Pingsheng Huang, Yanming Wang, Weiwei Wang, Chen Li, Deling Kong
The purpose of the present study was to identify an "easy-to-adopt" strategy to enhance immune responses using functionalized alginate (ALG) nanoparticles (MAN-ALG/ALG=OVA NPs), which were prepared by CaCl2 cross-linking of two different types of ALG. The mannose (MAN) modified ALG (MAN-ALG) was used for dendritic cell targeting. The other component, composed of ovalbumin (OVA), a model antigen, is conjugated to ALG (ALG=OVA) via pH sensitive Schiff base bond. Grafting of alginate was demonstrated by FT-IR and (1)H NMR, while the morphological structure, particle size, Zeta potential of MAN-ALG/ALG=OVA NPs were measured using TEM and DLS...
April 13, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
keyword
keyword
54124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"